Cerep licenses eye disease compound to Thea
This article was originally published in Scrip
Cerep has licensed an LFA-1 receptor antagonist with potential for treating eye disease to Théa for an undisclosed sum. Last year the two firms identified a new topical indication for the antagonist in ophthalmology which greatly reduces the risk of hepatotoxic effects. Bristol-Myers Squibb and Cerep stopped the original development programme in systemic immuno-inflammatory diseases after discovering hepatotoxic effects following oral administration. The licence agreement triggers a first payment to Cerep, followed by milestones and royalties once the drug reaches the market. Cerep will receive the first milestone after successful proof-of-concept, which will be started shortly. Thierry Jean, Cerep'spresident and CEO, said the new indication should reduce side-effects as it would most likely require a reduced dosage. LFA-1 is a key adhesion receptor in immune and inflammatory processes and acts as a signal-transducing molecule.
You may also be interested in...
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.